Browse Category

NYSE:TAK News 21 August 2025 - 11 October 2025

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership & Culture: President
Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Biotech Breakthroughs & Pharma Shakeups – Global Health Roundup (Aug 20–21, 2025)

Industry & Corporate Developments Mergers, Acquisitions & Partnerships Regulatory & Drug Approval Updates Public Health & Policy Research & Clinical Breakthroughs Sources: Reuters, Politico, HealthLeaders, BioPharma Dive, FierceBiotech, Pharmaceutical Executive, Technology Networks, McGill University reuters.com reuters.com healthleadersmedia.com reuters.com fiercebiotech.com reuters.com reuters.com technologynetworks.com technologynetworks.com.

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 08.02.2026

8 February 2026
LIVEMarkets rolling coverageStarted: February 8, 2026, 12:00 AM ESTUpdated: February 8, 2026, 1:08 AM EST Wheaton Precious Metals CEO Succession and Valuation Analysis February 8, 2026, 1:01 AM EST. Wheaton Precious Metals (TSX:WPM) announced Haytham Hodaly will become CEO on March 31, 2026, with Randy Smallwood moving to non-executive Chair. The stock has surged nearly 30% in 90 days and posted a 98% one-year total return. Despite this momentum, shares trade about 22% below an analyst's fair value estimate of CA$190.41. The company boasts strong finances with CA$1 billion cash and a CA$2 billion undrawn credit facility, underpinning growth prospects.
Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

Tower Semiconductor stock jumps again on Nvidia optics tie-up as earnings near

8 February 2026
Tower Semiconductor shares rose 7.7% to $139.04 Friday after announcing a collaboration with Nvidia on AI data-center networking. The stock touched $141 intraday and gained another 1% after hours. Investors await Tower’s Feb. 11 earnings for details on its silicon photonics work. No financial terms or shipment timeline were disclosed.
Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Longsys disclosed new guarantees for a 100 million yuan Hong Kong loan and a $9 million Brazil credit line, bringing its total approved guarantee quota to 11 billion yuan and outstanding guarantees to 5.81 billion yuan. The company said all guarantees are for consolidated subsidiaries and within approved limits. Shares closed at 288 yuan Friday, down 1.6%. China inflation and credit data are due this week.
Go toTop